Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCT00104572 | |||
| 04-AG-N338 | Other Identifier | NIHCC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body. This is associated with negative effects on muscle strength, bone density, sexual function, mood, and the ability to think to the best of one's ability. Testosterone replacement therapy often involves injections, patches, or gels that help to raise circulating testosterone levels, but these therapies often have side effects because they lead to imbalance of other hormones. Researchers have been studying the effectiveness of anastrozole, a drug that can lower estrogen levels while simultaneously increasing testosterone levels, as a treatment for the negative effects of decreased circulating testosterone levels that occur naturally with aging. Objectives: To evaluate whether anastrozole is as effective as testosterone gel in improving bone and muscle strength, hormone levels, and brain function in men over 65 years of age. Eligibility: Healthy men at least 65 years of age who have low levels of testosterone. Design: The study involves six study visits over a total of 12 months: screening, baseline, 6 weeks, 3 months, 6 months, and 12 months. All participants will receive calcium and vitamin D supplements to take daily, and will be randomized to one of three groups:Testosterone gel and placebo tablet, Anastrozole tablet and placebo gel, Placebo tablet and gel. Participants will have the following tests at each specified visit:Screening: Blood tests and rectal ultrasound to evaluate the prostate;Baseline: Blood and urine tests; growth hormone levels, muscle strength, bone density, and balance evaluation; imaging studies; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six weeks: Blood tests and dose adjustment of the gel or tablet;Three months: Blood and urine tests; growth hormone, muscle strength, bone density, and balance evaluation; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six months: Blood and urine tests; muscle strength, bone density, and balance evaluation; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Twelve months: Blood and urine tests; rectal ultrasound; muscle strength, bone density, and balance evaluation; imaging studies; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms.
Approximately 20% of men over the age of 70 have low testosterone levels. In some studies, testosterone replacement has resulted in improvement in bone mass, muscle strength, quality of life and memory function. In the body, testosterone is converted into estrogen. Hence, it is unclear whether these beneficial effects are due to testosterone or estrogen. Research has shown that inhibition of estrogen production in men results in an increase in testosterone levels.
In this study, patients will be assigned to one of three groups: one group will receive testosterone gel and a placebo tablet, one group will receive a 1mg Anastrozole tablet and a placebo gel, and one group will receive a placebo tablet and placebo gel. Each group will receive a daily dose of calcium with vitamin D. The study requires 6 visits over a 12-month period for testing and evaluation. Two of the 6 visits will require an overnight stay in the hospital so that an intravenous (IV) line can be placed in the arm to allow samples to be drawn throughout the night. Testing will include a cardiac stress test, a glucose tolerance test, bone and muscle tests, evaluation of memory function, etc. For the safety of the prostate, we will perform a prostate ultrasound at the start and end of the study and we will monitor urinary symptoms, prostate specific antigen (PSA) levels and the prostate exam throughout the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| (Androgel) testosterone gel | Experimental | 17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU' |
|
| anastrozole (Aromatase inhibitor) | Experimental | 14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU' |
|
| placebo | Placebo Comparator | 13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU' |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Androgel (Testosterone Gel) | Drug | 1 mg tablet for 12 months |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density | bone mineral density lumbar spine for all arms testosterone gel, anastrozole and placebo | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of Testosterone Gel vs. Anastrozole on Pulsatile Growth Hormone Release | Overnight Growth hormone measures (total hormone secretion) for groups testosterone gel, anastrozole and placebo | 1 year |
| Effect of Testosterone Gel vs. Anastrozole on Glucose Tolerance/Lipid Metabolism |
Not provided
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
History of Stroke
History of Dementia
History of Diabetes
Blood pressure at rest of > 155/90 mmHg. Elevated systolic or diastolic reading renders subject ineligible
Chronic medical condition, i.e. congestive heart failure
Arthritis, severe enough to prevent completion of the strength testing, history of joint replacement of knees or hip.
Inability to walk 50 meters
Known disease of the bone and/or taking medications to treat osteoporosis, i.e.
Fosamax, Evista, Miacalcin
History of Gastric surgery
History of prostate cancer or any other cancers, including blood dyscrasias
History of severe benign prostatic hyperplasia (causing urinary problems)
History of heart attack or open-heart surgery within the past 6 months
Use of steroids within the past 3 months, including prednisone and/or cortisone injections, and inhaled steroids. Topical steroid cream is acceptable.
If you do not agree to refrain from taking the drugs Viagra, Cialis or Levitra for the duration of the study
Use of anabolic steroids, i.e. testosterone, (or any analog of testosterone) Dehydroepiandrosterone or any growth promoters i.e. growth hormone itself or analogs of growth hormone
Use of anti-androgen medications, i.e. Aldactone, Tagamet, Proscar, estrogens
Use of Dilantin or Phenobarbital
Alcohol intake > 30 grams (drink more than 2 beers per day OR more than 1 glass of wine or cocktail daily)
Currently smokes any tobacco product
Having started a new medication during the past three months which may interfere with the outcome measures of the study
Polycythemia
Prostate specific antigen > 4.0 ng/dl
Hematocrit < 36
Liver function tests greater than 2 times upper normal limits or abnormal electrolytes, calcium or Parathyroid hormone , at the discretion of the investigator
Mini Mental Status Exam score less than or equal to 24
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Josephine M Egan, M.D. | National Institute on Aging (NIA) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institute of Aging, Clinical Research Unit | Baltimore | Maryland | 21224 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 4290227 | Background | Jeffcoate SL, Brooks RV, Lim NY, London DR, Prunty FT, Spathis GS. Androgen production in hypogonadal men. J Endocrinol. 1967 Apr;37(4):401-11. doi: 10.1677/joe.0.0370401. No abstract available. | |
| 7486793 | Background | Wheeler MJ. The determination of bio-available testosterone. Ann Clin Biochem. 1995 Jul;32 ( Pt 4):345-57. doi: 10.1177/000456329503200401. No abstract available. |
Not provided
Not provided
The study randomized 44 subjects, however 9 of them stop the study before having the second visit completed, so we started the analysis with 35 subjects. The participant flow module has 35 subjects, because these subjects have a baseline and 3 months endpoints.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Transdermal Testosterone | 13 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months Androgel (Testosterone Gel): 1 mg tablet for 12 months Placebo tablet: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Anastrozole (Aromatase Inhibitor) |
| Drug |
|
| Placebo tablet | Drug | Daily for 12 months |
|
| Placebo gel | Drug | Daily for 12 months |
|
| Calcium Cardone 500mg with vitamin D 400 IU | Dietary Supplement | 1 tablet three times a day |
|
Primary outcome HOMA-IR for all groups testosterone gel, anastrozole and placebo Insulin resistance measure by HOMA-IR is a score if a person is insulin resistance the score should be between minimum 0.7- maximum 2 or more. Absolute changes in HOMAIR in all treatment arms, calculation time frame 1 year minus baseline point. |
| 1 year |
| Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function | rectal ultrasound prostate volume for all groups testosterone gel, anastrozole and placebo. Absolute changes in prostate volume in all treatment arms, calculation time frame 1 year minus baseline point. | 1 year |
| 1719016 | Background | Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991 Nov;73(5):1016-25. doi: 10.1210/jcem-73-5-1016. |
| 26950683 | Derived | Dias JP, Melvin D, Shardell M, Ferrucci L, Chia CW, Gharib M, Egan JM, Basaria S. Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men. J Clin Endocrinol Metab. 2016 Apr;101(4):1865-71. doi: 10.1210/jc.2016-1111. Epub 2016 Mar 7. |
| Aromatase Inhibitor |
13 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months Anastrozole (Aromatase Inhibitor) Placebo gel: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day |
| FG002 | Placebo | 9 participants will receive a placebo tablet and placebo gel daily for 12 months Placebo tablet: Daily for 12 months Placebo gel: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Transdermal Testosterone | participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months Androgel (Testosterone Gel): 1 mg tablet for 12 months Placebo tablet: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day |
| BG001 | Aromatase Inhibitor | participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months Anastrozole (Aromatase Inhibitor) Placebo gel: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day |
| BG002 | Placebo | participants will receive a placebo tablet and placebo gel daily for 12 months Placebo tablet: Daily for 12 months Placebo gel: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| Systolic blood pressure | Mean | Standard Deviation | mmHg |
| |||||||||||||||
| Diastolic blood pressure | Mean | Standard Deviation | mmHg |
| |||||||||||||||
| Body mass index | Mean | Standard Deviation | kg/m2 |
| |||||||||||||||
| Total Testosterone | Mean | Standard Deviation | ng/dL |
| |||||||||||||||
| Bioavailable Testosterone | Mean | Standard Deviation | ng/dL |
| |||||||||||||||
| Estradiol | Mean | Standard Deviation | ng/dL |
| |||||||||||||||
| Sex hormone-binding globulin | Mean | Standard Deviation | nmol/L |
| |||||||||||||||
| luteinizing hormone | Mean | Standard Deviation | mlU/ml |
| |||||||||||||||
| follicle-stimulating hormone | Mean | Standard Deviation | mlU/ml |
| |||||||||||||||
| Bone mineral density | Mean | Standard Deviation | g/cm2 |
| |||||||||||||||
| lean body mass | Mean | Standard Deviation | kg |
| |||||||||||||||
| Fat mass | Mean | Standard Deviation | kg |
| |||||||||||||||
| hand grip | Mean | Standard Deviation | kg |
| |||||||||||||||
| knee strength | Mean | Standard Deviation | Nm |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density | bone mineral density lumbar spine for all arms testosterone gel, anastrozole and placebo | Posted | Mean | Standard Deviation | g/cm2 | 1 year |
|
|
| ||||||||||||||||||||||||||||||||
| Secondary | Effect of Testosterone Gel vs. Anastrozole on Pulsatile Growth Hormone Release | Overnight Growth hormone measures (total hormone secretion) for groups testosterone gel, anastrozole and placebo | Posted | Mean | Standard Error | ng/ml/8h | 1 year |
| ||||||||||||||||||||||||||||||||||
| Secondary | Effect of Testosterone Gel vs. Anastrozole on Glucose Tolerance/Lipid Metabolism | Primary outcome HOMA-IR for all groups testosterone gel, anastrozole and placebo Insulin resistance measure by HOMA-IR is a score if a person is insulin resistance the score should be between minimum 0.7- maximum 2 or more. Absolute changes in HOMAIR in all treatment arms, calculation time frame 1 year minus baseline point. | Posted | Mean | Standard Error | score on a scale | 1 year |
| ||||||||||||||||||||||||||||||||||
| Secondary | Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function | rectal ultrasound prostate volume for all groups testosterone gel, anastrozole and placebo. Absolute changes in prostate volume in all treatment arms, calculation time frame 1 year minus baseline point. | Posted | Mean | Standard Error | cc | 1 year |
|
Not provided
The study randomized 44 subjects, however 9 of them stop the study before having the second visit completed, so we started the analysis with 35 subjects. The participant flow module has 35 subjects, because these subjects have a baseline and 3 months endpoints.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Transdermal Testosterone | participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months Androgel (Testosterone Gel): 1 mg tablet for 12 months Placebo tablet: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day | 3 | 17 | 0 | 17 | ||
| EG001 | Aromatase Inhibitor | participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months Anastrozole (Aromatase Inhibitor) Placebo gel: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day | 6 | 14 | 0 | 14 | ||
| EG002 | Placebo | participants will receive a placebo tablet and placebo gel daily for 12 months Placebo tablet: Daily for 12 months Placebo gel: Daily for 12 months Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day | 3 | 13 | 0 | 13 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| muscle ache | Musculoskeletal and connective tissue disorders | Systematic Assessment | in aromatase group |
| |
| bladder mass | Renal and urinary disorders | Systematic Assessment | bladder mass on transrectal exam |
| |
| subdural hematoma | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| stent placement | Vascular disorders | Systematic Assessment |
| ||
| Dyspnea on exertion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| mildly elevated HCT | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| elevated PSA | Reproductive system and breast disorders | Systematic Assessment |
| ||
| increased heart rate palpitations | Cardiac disorders | Systematic Assessment |
| ||
| dizziness/diarrhea | General disorders | Systematic Assessment |
| ||
| elevated PSA | Reproductive system and breast disorders | Systematic Assessment |
| ||
| blood in semen | Reproductive system and breast disorders | Systematic Assessment |
| ||
| muscle ache | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Josephine M. Egan,MD, clinical director NIA | NIA | 410-558-8414 | eganj@grc.nia.nih.gov |
| ID | Term |
|---|---|
| D007006 | Hypogonadism |
| D003920 | Diabetes Mellitus |
| D055948 | Sarcopenia |
| D010024 | Osteoporosis |
| D003863 | Depression |
| ID | Term |
|---|---|
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D013739 | Testosterone |
| D000077384 | Anastrozole |
| D047072 | Aromatase Inhibitors |
| D014807 | Vitamin D |
| ID | Term |
|---|---|
| D000737 | Androstenols |
| D000736 | Androstenes |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D045165 | Testosterone Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D065088 | Steroid Synthesis Inhibitors |
| D004791 | Enzyme Inhibitors |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D004965 | Estrogen Antagonists |
| D006727 | Hormone Antagonists |
| D045505 | Physiological Effects of Drugs |
| D012632 | Secosteroids |
Not provided
Not provided
| Male |
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|